Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech develops pelareorep, an investigational systemically delivered immunotherapy for cancer that has been shown to activate innate immune-sensing pathways. Company news centers on pelareorep clinical and translational data, FDA interactions, and study activity across gastrointestinal and other solid tumor indications, including metastatic colorectal cancer, squamous cell anal carcinoma, pancreatic cancer, and breast cancer.
Recurring updates also cover the company's registration-focused development priorities, Fast Track Designation for pelareorep-based treatment in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, scientific meeting presentations, financing arrangements, and its completed change of jurisdiction to Nevada while ONCY common stock continues to trade on Nasdaq.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced the acceptance of an abstract for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 2-6, 2023 in Chicago, Illinois. The presentation will focus on the BRACELET-1 trial, which evaluates the use of pelareorep in combination with paclitaxel and avelumab for treating metastatic HR+/HER2- breast cancer. Dr. Matt Coffey, CEO, emphasized the significance of this recognition, stating it highlights the trial's importance to oncology stakeholders. The abstract, numbered 1012, will be published on the ASCO website on May 25, 2023. Oncolytics is advancing pelareorep through several clinical trials aimed at enhancing treatment outcomes for various cancers.
Oncolytics Biotech announced that Chief Medical Officer Thomas Heineman will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 20, 2023. The event starts at 9:00 a.m. ET, and a live webcast will be accessible to registered attendees. Company management will also engage in virtual one-on-one investor meetings throughout the conference. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent designed to enhance anti-cancer immune responses for various cancers. The company is advancing clinical trials to evaluate pelareorep in combination with other treatments for conditions like metastatic breast and pancreatic cancer.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on May 5, 2023, at 8:30 a.m. ET to discuss the first quarter financial results and provide a corporate update. The call can be accessed via toll-free numbers for North America and international callers, and a replay will be available for one week post-event. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing anti-cancer immune responses. The company is exploring combinations of pelareorep with checkpoint inhibitors and other oncology treatments, particularly targeting metastatic breast cancer and pancreatic cancer. For further details, visit Oncolytics Biotech's website.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has released its annual general meeting notice, which will take place virtually on May 9, 2023, at 4:00 p.m. Toronto time. Shareholders can view the management information circular on the company's website. Proxy solicitation is being handled by Laurel Hill Advisory Group, with a fee of $35,000 plus expenses. Shareholders are urged to vote before the 4:00 p.m. deadline on May 5, 2023. The board of directors recommends voting for all nominees and resolutions. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent aimed at enhancing anti-cancer immune responses, with ongoing clinical trials.